



Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Elizabeth Wehler¹ · Natalie Boytsov² · Claudia Nicolay³ · Oscar Herrera-Restrepo⁴ · Stacey Kowal⁴

Published online: 12 November 2019
© The Author(s) 2019

Correction to: PharmacoEconomics
<https://doi.org/10.1007/s40273-019-00829-x>

Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.

The last line of the results section of the abstract should read “The cost per additional responder for baricitinib in patients with inadequate response to a TNFi was substantially lower than all other treatments for all three ACR response criteria at 12 weeks (ACR20: \$US129,672; ACR50: \$US237,732; ACR70: \$US475,464), among the lowest at 24 weeks for ACR20 and ACR50 (\$US167,811 and \$US259,344, respectively), and similar to other products at ACR70 (\$US570,557).”

In Sect. 3.2, the 3rd sentence of the last paragraph should read “For ACR70 at 24 weeks, tocilizumab, abatacept and sarilumab had the lowest cost per responder followed by baricitinib.”

In the Discussion, the 5th sentence of the first paragraph should read “At 24 weeks, baricitinib was second to tocilizumab for ACR20 and ACR50, and fourth to tocilizumab, abatacept and sarilumab for ACR70.”

In Table 2, columns 2 and 3, the annual drug cost of sarilumab should be \$43,533. In Table 2, columns 6 and 7 the

total costs for sarilumab should be \$43,788 and \$43,656, respectively.

In Table 5, column 2, the annual cost of sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$43,966. In Table 5, column 5, the cost per additional responder for sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$169,098, \$274,785 and \$549,569, respectively. In Table 5, column 8, the cost per additional responder for sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$183,190, \$274,785 and \$549,569, respectively.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40273-019-00829-x>.

✉ Elizabeth Wehler
beth.wehler@iqvia.com

¹ IQVIA, 1 IMS Drive, Plymouth Meeting, PA 19462, USA

² Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

³ Lilly Deutschland GmbH, Bad Homburg, Germany

⁴ IQVIA, 3110 Fairview Park Drive, Falls Church, VA 22042, USA